#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Colorectal cancer metastatic Obesity Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Non-small cell lung cancer metastatic Asthma Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    IPEX syndrome Small for dates baby Ventricular fibrillation SAPHO syndrome Antithrombin III deficiency Cardiac arrest Alexander disease Polycythaemia vera Henoch-Schonlein purpura Neonatal alloimmune thrombocytopenia Candida infection Angiosarcoma recurrent Orthostatic hypotension Biliary neoplasm Advanced systemic mastocytosis More trials…

    Learn about Rare Diseases

    Chondrosarcoma metastatic Familial haemophagocytic lymphohistiocytosis – Trials in Disease Richter’s syndrome – Life with Disease Splenic marginal zone lymphoma – Basic Information Primary hyperoxaluria Usher’s syndrome – Basic Information Idiopathic pulmonary fibrosis – Life with Disease Prolymphocytic leukaemia – Basic Information Haemophilia B with anti factor IX Aicardi-Goutieres syndrome – Diagnostics More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Doxorubicin Enoxaparin Sodium Abc-23A-116 Omp12 Islatravir Piritramide Gemcitabine Lebrikizumab Sar-443579 Nefopam Hydrochloride Peginterferon Beta-1A Fostemsavir Gskvx000000009151 Roginolisib Cabozantinib Narsoplimab SEVABERTINIB Ziltivekimab Bemnifosbuvir Hemisulfate Ribonucleic Acid K10 More therapies…

    Learn about Your Condition

    Pancreatic fistula Pulmonary alveolar haemorrhage Frontotemporal dementia Mitral valve prolapse Sciatica Bacterial infection Rhinitis allergic Ependymoma malignant Eosinophilic gastritis Cutaneous T-cell lymphoma Urinary tract infection Behavioural addiction Hyperparathyroidism primary Erythema multiforme Seizure More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Dermatitis atopic

  • Study of GHZ339 for treatment of moderate to severe atopic dermatitis

    Recruiting

    2 1 1
    Investigated Diseases:
    • Dermatitis atopic
    Investigated Drugs:
    • Pimecrolimus
    • Tacrolimus
    Czechia France Germany Hungary Italy The Netherlands +3

  • Study on the Safety and Effectiveness of Upadacitinib and Dupilumab for Children Aged 2 to 12 with Moderate to Severe Atopic Dermatitis

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Dupilumab
    • Upadacitinib
    Austria Bulgaria Croatia France Germany Hungary +6

  • Phase 2b Randomized Double‑Blind Study of Oral PF‑08049820 in Adults with Moderate to Severe Atopic Dermatitis

    Not yet recruiting

    2 1
    Investigated Diseases:
    • Dermatitis atopic
    Bulgaria Czechia France Germany Poland

  • A Study of Lebrikizumab for Adults and Adolescents with Moderate to Severe Atopic Dermatitis to Evaluate Effects on Eczema and Skin Barrier Function

    Not yet recruiting

    3 1 1 1
    Investigated Diseases:
    • Dermatitis atopic
    Investigated Drugs:
    • Lebrikizumab
    Sweden

  • Testing GIA632 compared to placebo in adults with moderate to severe atopic dermatitis to measure effectiveness and safety

    Not yet recruiting

    2 1
    Investigated Diseases:
    • Dermatitis atopic
    Bulgaria Czechia France Germany Poland

  • Study of Lebrikizumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis to Understand How the Medicine Works

    Not yet recruiting

    3 1 1 1
    Investigated Diseases:
    • Dermatitis atopic
    Investigated Drugs:
    • Lebrikizumab
    Germany
Previous Page
1 2 3 4 5 … 14
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!